Bafna Pharmaceuticals Limited

NSE:BAFNAPH.NS

79.14 (INR) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 1,524.6571,153.499851.404712.179424.725433.589471.707649.615853.184976.7491,853.3941,757.7071,256.6211,019.242751.813472.537396.068372.464
Cost of Revenue 1,309.3765.94512.858454.555270.236345.693438.919577.736729.17916.6271,355.881,329.111980.348859.885629.742356.955367.398351.756
Gross Profit 215.357387.559338.546257.624154.48987.89632.78871.88124.01460.122497.514428.596276.273159.357122.072115.58228.6720.708
Gross Profit Ratio 0.1410.3360.3980.3620.3640.2030.070.1110.1450.0620.2680.2440.220.1560.1620.2450.0720.056
Reseach & Development Expenses 15.3627.21214.72813.58910.0957.5273.7097.1858.1699.55711.6270000000
General & Administrative Expenses 014.80315.8147.21812.1165.4697.8324.4529.192111.23415.08521.957020.37913.6089.5045.3864.99
Selling & Marketing Expenses 05.62523.426.483.6788.0984.7527.9380.79117.23749.32136.913011.5237.3634.9843.1764.017
SG&A 154.19920.42839.23413.69815.79413.56712.58412.38829.983128.471243.535198.348031.90220.97114.4898.5629.007
Other Expenses 35.22432.72712.6090.0740.0754.087.5650.0530.0550.055344.070.1283.19640.10422.82819.2275.6684.505
Operating Expenses 154.199283.747274.197196.243174.097159.135160.87164.767153.073251.612344.07283.675138.04261.1353.68963.6439.8653.719
Operating Income 61.158117.72366.4161.456-19.747-162.819-128.082-203.627-153.19260.67224.91254.921138.23198.22768.38351.93918.80516.99
Operating Income Ratio 0.040.1020.0780.086-0.046-0.376-0.272-0.313-0.180.0620.0130.0310.110.0960.0910.110.0470.046
Total Other Income Expenses Net 12.321-1.56-14.247-3.1890.967-20.11-19.084-110.74-124.133252.161-128.532-90-84.517-50.849-28.731-27.186-5.828-5.82
Income Before Tax 73.479116.16373.07658.267-18.834-182.928-147.166-203.627-153.19260.67224.91254.92153.71447.37739.65224.75312.97711.17
Income Before Tax Ratio 0.0480.1010.0860.082-0.044-0.422-0.312-0.313-0.180.0620.0130.0310.0430.0460.0530.0520.0330.03
Income Tax Expense 49.7862.78312.56-2.303229.70710.67421.927-9.03-1.778-1.52610.46814.78934.65913.89714.83814.0780.9921.485
Net Income 73.479113.3852.16358.267-247.293-188.704-167.365-190.868-140.26961.77414.03639.62718.40833.48124.81310.67511.9859.685
Net Income Ratio 0.0480.0980.0610.082-0.582-0.435-0.355-0.294-0.1640.0630.0080.0230.0150.0330.0330.0230.030.026
EPS 3.114.792.212.46-104.54-7.98-9.24-10.43-8.83.280.752.141.041.921.550.741.522.51
EPS Diluted 3.114.792.212.46-104.54-7.98-9.24-10.43-8.83.280.752.141.041.921.550.741.522.51
EBITDA 111.112189.883133.251103.93514.113-32.824-82.245-49.0368.496-138.022243.383226.094201.259118.02785.40464.26822.26220.096
EBITDA Ratio 0.0730.1650.1570.1460.033-0.076-0.174-0.0750.01-0.1410.1310.1290.160.1160.1140.1360.0560.054